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Abstract
Background: Managing oral anticoagulant treatment (OAT) is a challenge for patients and primary care providers.
It requires a high level of patient knowledge and adherence. Studies have shown that insufficient adherence and a
low level of patient knowledge about OAT are primary causes for complications. This trial is the first to evaluate
the long-term effects of a complex practice nurse-based patient education program in comparison to a patient
brochure only.
Methods and design: This trial will be a cluster-randomized controlled trial in 22 general practices (GPs)
recruiting 360 patients with OAT. GPs will be randomized into an intervention group or a control group. A
baseline questionnaire will assess pre-existing knowledge about OAT. The patients in the intervention group will
be educated by a complex education program which consists of a video, a brochure and individual training by
a practice nurse. The video gives information about OAT, nutrition, and instructions about how to manage
critical situations. The brochure repeats the content of the video. After 4 to 6 weeks, the intervention will be
recapitulated. The control group will receive the brochure only. After 6 months, questionnaires will be used in
both groups to assess patient knowledge about OAT as well as patients’ subjective feelings of safety. Separately,
we will evaluate patient records, looking for documented complications and the time spent in the therapeutic
range.
Discussion: This trial will start in January 2011. This trial will evaluate the long-term effectiveness of a video-
assisted education program on patients with OAT in comparison to a patient information brochure. Most previous
studies have evaluated knowledge directly after an educational intervention. Our trial will look for long-term
differences in basic knowledge of OAT. We expect that our complex patient education program effectively
increases long-term basic knowledge about OAT. Although the population of our study is too small to observe
differences in adverse effects, we expect to discover differences in secondary outcomes, such as the time spent in
the therapeutic range.
Trial registration: Deutsches Register Klinischer Studien (German Clinical Trials Register): DRKS00000586
Universal Trial Number (UTN U1111-1118-3464)
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Managing oral anticoagulant treatment (OAT) is a chal-
lenge for patients in their daily life. In Germany, more
than a half million patients are taking phenprocoumon
daily and this number will increase in the next few years
due to the demographic development, as in other indus-
trialized countries. The incidence and prevalence of
atrial fibrillation (AF), the major indication for oral
anticoagulation, increases progressively with age, and
approximately 50% of patients with AF are 75 years or
older. With the aging of population, the number of
adults with AF and OAT will increase markedly over
the next several decades [1]. Intra- and inter-individual
variability of the dose-effect relationship is affected by
several factors such as patient adherence, nutritional
patterns, genetic differences and drug interactions [2-4].
Serious complications arise from insufficient or exces-
sive anticoagulation. Main complications of OAT are
bleeding complications, which occur in 0.3 to 0.4% of all
patients with OAT every year [5]. Unlike in many other
countries, in Germany phenprocoumon is the most
commonly-used drug for OAT. An accurate estimation
of the complication rate in association with phenprocou-
mon does not exist. An English study assessed an
annual bleeding risk of 9.0% for Warfarin which is
usually prescribed in USA and the United Kingdom [6].
Lack of patient education, misjudgements of the indica-
tion, incorrect and misleading documentation, insuffi-
cient communication and cooperation as well as lack of
patient’s integration into the therapy are common causes
for an unsatisfactory management of OAT [7]. Studies
have confirmed that insufficient adherence and a low
level of patient knowledge about OAT are the primary
causes for complications [7-9]. Therefore, it is necessary
to increase patient knowledge. Patient self-management
(PSM) of international normalized ratio (INR) shows that
intensive obligatory training lowers the risk for severe
bleeding complications [10-12]. A systematic review con-
cluded that PSM is not feasible for many patients because
of patients’ inability to complete training [13,14].
Another barrier for implementation of PSM is costs [15].
A standardized education program in primary care for
patients who are not suitable for PSM is lacking in many
countries [7,9]. The best strategy for educating patients
about oral anticoagulation has not been determined yet
[16]. In Germany, general practitioners manage patients
with OAT. Some general practitioners use self-written
patient information brochures to inform patients about
OAT. However, the contents and quality of these bro-
chures can differ greatly and sometimes even contradict
evidence from published literature.
So far, an Italian study has evaluated the short-term
effects of an education program which was well
accepted by the patients but did not improve the time
spent in the therapeutic range in the short term [17]. In
contrast, a French study could show that an education
program lowers the complication rate of patients with-
out PSM [18]. An Italian study assessed the acceptance
of an educational program for patients with OAT but
not its effectiveness [19].
Based on these studies, our trial is the first to evaluate
the long-term effects of a complex practice nurse-based
patient education program in comparison to a patient
brochure only.
Hypothesis
A practice nurse-based, individual and video-assisted
patient education program effectively increases long-
term basic knowledge about OAT. Patients participating
in this complex education program will spend more
time in the therapeutic range and will have fewer com-
plications in comparison to the control group.
Aim
The aim of this trial is to evaluate the long-term effects
of a complex patient education program about OAT in
comparison to a patient information brochure only.
Objectives
▪ To investigate long-term effectiveness (6 months)
of a complex patient education program about OAT
on patient knowledge
▪ To assess the effect of a complex patient educa-
tion program about OAT on time spent in therapeu-
tic range
▪ To investigate long-term effectiveness (6 months)
of a complex patient education program about OAT
on subjective feeling of safety
▪ To assess effect of a complex patient education
program about OAT on complications related to
OAT
Method
This trial will be a cluster-randomized controlled educa-
tional trial consisting of 22 general practices (GPs)
which are expected to recruit 360 patients with OAT.
Practices will be randomized into an intervention group
or a control group (Figure 1).
We obtained a Universal Trial Number (UTN: U1111-
1118-3464) and registered this trial in the German Clini-
cal Trials Registry (DRKS00000586).
Patient recruitment
General practitioners
Monitoring and dose adjustment for OAT is managed
by general practitioners in Germany. GPs in central
Germany (Göttingen, Braunschweig and the surrounding
areas) will be invited to participate in the trial by mail.
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boards. In case of non-response to the letter, GPs will
be contacted by telephone or personally. From previous
experience, it seems likely that roughly 15 - 20% will
agree to participate [20].
Patients
In order to minimize sub-sampling bias, all patients with
OAT will be identified at the beginning of the trial by
searching the GPs’ electronic medical records for the
laboratory billing code “32015” for INR measurement. The
inclusion criteria are age (> 18 years), OAT and willing-
ness to participate in the trial. For dependent patients,
both they and their caregivers (e.g. care giving relatives)
must be willing to participate. Exclusion criteria include
the inability to give informed consent and/or the lack of a
caregiver willing to participate in the study. Also, nursing
home residents, patients only seen in cross coverage, or
patients with an insufficient command of the German lan-
guage will be excluded. Lastly, patients managing anticoa-
gulation with self-monitoring (PSM) will also be excluded.
During their next visit for INR-measurement age and
gender of all eligible patients will be recorded. Patients
will receive an information leaflet regarding the purpose
and content of the study. Patients willing to participate
will fill in a consent form. If there are further questions,
patients, caregivers and/or practice nurses are encour-
aged to contact the study doctors.
Randomization
The randomization of the GPs to the intervention or
control group will be conducted externally by
Department of Medical Statistics, University Medical
Centre Göttingen using a computer routine (allocation
ratio 1:1).
Primary outcome
The primary outcome is the number of correctly
answered questions from the 13-item OAT-
questionnaire.
Secondary outcome
Secondary outcomes are time spent in therapeutic
range, subjective feeling of safety and complications
related to OAT.
Intervention
Practice nurses will attend a preparatory course, which
will enable them to provide individual training sessions
for patients based on the content of the video and bro-
chure. The preparatory course for the practice nurses
will include simulation (role play).
Patients in the intervention group will be shown an
educational video and receive a patient information bro-
chure. The video (20 minutes) provides information
about OAT based on up-to-date scientific literature. It
addresses common questions about OAT (Table 1). The
patient information brochure was designed in accor-
dance with the DISCERN criteria and complements the
video [21].
Practice nurses will use the brochure as a guide to dis-
cuss knowledge gaps about OAT after the video in an
individual training session lasting about 20-30 minutes.
The intervention group has the option of another indivi-
dual training if necessary. After 4 to 6 weeks when the
next blood work is done, patients will be asked to fill in
a short knowledge assessment questionnaire, designed
to recap what was learned in the video and individual
training session.
Control
The control group will only receive the patient informa-
tion brochure.
Data collection
D e m o g r a p h i cd a t aa n dk n o w l e d g ea b o u tO A Tw i l lb e
collected at baseline (Additional file 1). After six
months, knowledge about OAT and the subjective feel-
ing of safety in both groups will be assessed (Figure 1).
The self-developed questionnaire is based on the con-
tent of the video and the information brochure. The
questionnaire was piloted with 12 patients previously
and optimized accordingly.
At the end of the trial after 6 months we will collect
data about complications related to OAT and the INR
results from patient records in both groups.
Figure 1 Flow-chart. The flow-chart gives an overview about the
trial.
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All data will be handled according to the Medical Confi-
dentiality Rules and German Federal Data Security Law.
Patient names and other confidential information will be
coded to disable the tracking of individual patients.
Informed consent and questionnaires will be mailed
separately.
Ethics
The trial is planned and will be conducted in accor-
dance to the medical professional codex and the Hel-
sinki Declaration of 1996 as well as the German Federal
Data Security Law. The study protocol was approved by
the ethics committee of the University of Göttingen
(ethic committee University Medical Centre Göttingen,
protocol number 2/9/10). Patients receive written and
oral information about the flow of the study, its aims,
potential benefits and risks prior to their consent and
participation in the trial. If they agree to participate,
they sign the informed consent sheet. Patients are
informed that they may withdraw from the study at any
time without disclosing reasons and without negative
consequences for their medical care.
Statistical analysis
We expect a total number of 22 practices which will be
randomized to the two intervention arms. Assuming an
intra-cluster correlation coefficient of 0.05 [22], 15
patients per practice (i.e. 22 × 15 = 330 patients in
total) will give a power of at least 80% at a two-sided
significance level of 5% if the standardized intervention
effect is at least 0.41, which is considered a medium
effect size [23]. Accounting for patient dropout, we plan
to recruit a total of 360 patients, i.e. about 16 patients
per practice. We do not expect any practices to drop
out.
Baseline and follow-up data will be presented using
standard descriptive statistics and graphs. Allowing for
correlation the primary endpoint will be modelled in a
mixed linear model with intervention, baseline OAT
knowledge and, if imbalances between the groups occur,
possibly other factors as fixed effects and a practice
effect as a random cluster effect. Main interest is in test-
ing the null hypothesis of no intervention effect. The p-
value for this test will be reported alongside a 95% con-
fidence interval for the intervention effect. Standard
diagnostics will be applied to check for model fit. If
model assumptions are not met, non-parametric rank-
based procedures will be considered. The mixed linear
model described above is to some extent robust to miss-
ing data. If the proportion of missing data is much
higher than expected, alternatives will be explored [24].
Percentage time in range will be calculated according to
Rosendaal’s equation [25].
Discussion
To our knowledge this will be the largest cluster-rando-
mized controlled trial to evaluate the long-term effects
of a complex patient education program about OAT in
comparison to a patient information brochure only. An
educational video has been used previously in a small
American study (n = 22) [26]. So far, most studies only
evaluated the short-term effects of education programs
or assessed the acceptance of education programs for
patients with OAT but not its effectiveness [17,19].
Moreover most studies were done with patients trained
for self management (PSM).
Our trial will provide data about patient knowledge,
the effect of education on time spent within therapeutic
range and the rate of complications. Although we record
complications in our study, we expect that the frequency
will be too low to detect significant differences between
the groups. If we can prove an increase of long-term
knowledge of patients about OAT by a video-assisted
Table 1 Content of the video
1. Introduction
- aim of this video
- scene: a patient newly on oral anticoagulant therapy consults
her GP and has questions
2. General information about oral anticoagulation
- Why do I have to take oral anticoagulants?
- active agent: Phenprocoumon
- Explanation of stroke
- How long do I have to take oral anticoagulants?
- How do I notice that my coagulation not sufficiently
inhibited?
3. Nutrition
- Do I have to follow a special diet?
- Which food contains a high amount of vitamin K (usual
consumption quantity)?
- Alcohol, coffee
- Nutrition on holidays
4. Drug-interactions & influences on OAT
- Drug interactions, influence of non-prescription drugs (herbal
drugs)
- Discontinuation or prescription of a new drugs
- Which non-prescription pain-killer is the safest in
combination with oral anticoagulant therapy?
5. Adherence
- Monitoring
- Coagulation test, meaning of Quick- and INR-level,
therapeutic range
- What should I do if I forgot a dosage?
- Recognition of critical situations and how to react (e.g.
bleeding, black stool)
- In which situations should I mention that I receive oral
anticoagulants? (e.g. pharmacy, dentist, injections)
6. Summary of the main points
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into routine OAT in primaryc a r et oi n c r e a s ep a t i e n t
safety.
Recruitment into this study is scheduled to the start in
early 2011.
Additional material
Additional file 1: Annex - Baseline Questionnaire. A 13-item-
questionnaire to evaluate patient knowledge about OAT at baseline
(translation).
Abbreviations
The following abbreviations have been used in the manuscript:
INR: international normalized ratio; GP: general practitioners; OAT: oral
anticoagulation therapy; PSM: patient self-management.
Acknowledgements
The trial is funded by the German Ministry of Health (Project number 2509
ATS 005) within in the “National action plan for drug safety in Germany”
(Aktionsplan des Bundesministeriums für Gesundheit zur Verbesserung der
Arzneimitteltherapiesicherheit (AMTS) in Deutschland) http://www.akdae.de/
AMTS/index.html.
Author details
1Department of General Practice, University Medical Centre Göttingen,
Humboldtallee 38, Göttingen, 37073, Germany.
2Department of Clinical
Pharmacology, University Medical Centre Göttingen, Robert-Koch-Str. 40,
Göttingen, 37075, Germany.
3Department of Medical Statistics, University
Medical Centre Göttingen, Humboldtallee 32, Göttingen, 37073, Germany.
Authors’ contributions
All authors contributed to the study design and the making of the
educational video. Funding was obtained by JFC and SVV. TDH and JFC
were the principal authors of the manuscript. All authors reviewed and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 December 2010 Accepted: 10 April 2011
Published: 10 April 2011
References
1. Rich MW: Epidemiology of atrial fibrillation. J Interv Card Electrophysiol
2009, 25:3-8.
2. Rane A, Lindh JD: Pharmacogenetics of anticoagulants. Hum Genomics
Proteomics 2010, 2010:754919.
3. Wittkowsky AK: Dietary supplements, herbs and oral anticoagulants: the
nature of the evidence. J Thromb Thrombolysis 2008, 25:72-7.
4. Nutescu EA, Shapiro NL, Ibrahim S, West P: Warfarin and its interactions
with foods, herbs and other dietary supplements. Expert Opin Drug Saf
2006, 5:433-451.
5. Torn M, Bollen WL, van der Meer FJ, van der Wall EE, et al: Risks of oral
anticoagulant therapy with increasing age. Arch Intern Med 2005,
165:1527-32.
6. Burton C, Isles C, Norrie J, Hanson R, et al: The safety and adequacy of
antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J
Gen Pract 2006, 56:697-702.
7. Saal K, Hoffmann B, Blauth E, Rohe J, et al: Analyse des
Behandlungsprozesses bei der oralen Antikoagulationstherapie zur
Identifikation von Sicherheitsproblemen in der hausärztlichen
Versorgung [Analysis of the process of oral anti-coagulation therapy for
the identification of safety problems in primary care.]. Z Allg Med 2009,
85:148-155.
8. Wyse DG: Bleeding while starting anticoagulation for thromboembolism
prophylaxis in elderly patients with atrial fibrillation. Circulation 2007,
115:2684-6.
9. Kagansky N, Knobler H, Rimon E, Ozer Z, et al: Safety of antikoagulation
therapy in well-informed older patients. Arch Intern Med 2004,
164:2044-50.
10. Cromheecke ME, Levi M, Colly LP, de Mol BJ, et al: Oral anticoagulation
selfmanagement and management by a specialist anticoagulation clinic:
a randomised cross-over comparison. Lancet 2000, 356:97-102.
11. Sawicki PT, Glaser B, Kleespies C, Stubbe J, et al: Long-term results of
patients’ self-management of oral anticoagulation. Journal of Clinical &
Basic Cardiology 2003, 6:59-62.
12. Hasenkam JM, Kimose HH, Knudsen L, Gronnesby H, et al: Self
management of oral anticoagulant therapy after heart valve
replacement. Eur J of Cardiothorac Surg 2007, 11:935-942.
13. Heneghan C, Alonso-Coello JM, Parera R, et al: Self-monitoring of oral
anticoagulation: a systematic review and meta-analysis. Lancet 2006,
367:404-411.
14. Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, et al: Self-
monitoring and self-management of oral coagulation. Cochrane Database
of Sys Rev 2010, CD003839.
15. Wittkowsky AK, Sekreta CM, Nutescu EA, Ansell J: Barriers to patient self-
testing of prothrombin time: national survey of anticoagulation
practitioners. Pharmacotherapy 2005, 25:265-269.
16. Wofford JL, Wells MD, Singh S: Best strategies for patient education about
anticoagulation with warfarin: a systematic review. BMC Health Serv Res
2008, 8:40.
17. Barcellona D, Contu P, Marongiu F: A “two-step” educational approach for
patients taking oral anticoagulants does not improve therapy control. J
Thromb Thrombolysis 2006, 22:185-90.
18. Blaise S, Satger B, Fontaine M, Yver J, et al: Evaluation of an education
program for patients taking oral anticoagulations: Experience of the
Granted network in Isère. J Mal Vasc 2009, 34:346-53.
19. Corbella A, Bottari L, Cevasco I, Giacobbe S, et al: Patients in chronic
anticoagulation therapy: the organization of an educational program
run by nurses and the assessment of patients’ satisfation. Assist Inferm
Ric 2009, 28:65-72.
20. Hummers-Pradier E, Scheidt-Nave C, Martin H, Heinemann S, et al: Simply
no time? Barriers to GPs’ participation in primary health care research.
Fam Pract 2008, 25:105-112.
21. DISCERN-Online - Qualitätskriterien für Patienteninformationen. [http://
www.discern.de].
22. Campbell MK, Mollison J, Grimshaw JM: Cluster trials in implementation
research: estimation of intracluster correlation coefficients and sample
size. Statistics in Medicine 2001, 20:391-399.
23. Cohen JA: Statistical Power Analysis for the Behavioral Sciences. New
York: Lawrence Erlbaum Associates;, second 1988.
24. Molenberghs G, Kenward MG: Missing Data in Clinical Studies. Hoboken
NJ: John Wiley and Sons; 2007.
25. Rosendaal FR, Cannegieter SC, Van der Meer FJM, Briet E: A method to
determine the optimal intensity of oral anticoagulant therapy.
Thrombosis and Haemostasis 1993, 69:236-239.
26. Stone S, Holden A, Knapic N, Ansell J: Comparison between videotape
and personalized patient education for anticoagulant therapy. J Fam
Pract 1989, 29:55-7.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2296/12/17/prepub
doi:10.1186/1471-2296-12-17
Cite this article as: Hua et al.: Practice nursed-based, individual and
video-assisted patient education in oral anticoagulation - Protocol of a
cluster-randomized controlled trial. BMC Family Practice 2011 12:17.
Hua et al. BMC Family Practice 2011, 12:17
http://www.biomedcentral.com/1471-2296/12/17
Page 5 of 5